Silvia Iniesta Pérez

Silvia Iniesta Pérez


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Open access
JSJuan-Enrique Schwarze
Juan-Enrique Schwarze
CVChristos Venetis
Christos Venetis
SPSilvia Iniesta Pérez
Silvia Iniesta Pérez
EFEdel Falla
Edel Falla
VLVasily Lukyanov
Vasily Lukyanov
RMRoberto Matorras
Roberto Matorras
This study compared the cost per live birth and cost-effectiveness of the originator recombinant human follicle-stimulating hormone follitropin alfa (r-hFSH-alfa) and r-hFSH-alfa biosimilars for ovarian stimulation prior to assisted reproductive technology treatment in Spain. A decision tree model was developed, comprising pregnancy and live birth for one treatment cycle with fresh embryo transfer. Clinical inputs were based on a recent meta-analysis by Chua et al. [4]. Cost inputs were extracted from publicly available Spanish sources. The costs per live birth were lower with originator r-hFSH-alfa (€18,138) versus r-hFSH-alfa biosimilars (€20,377). The incremental cost-effectiveness ratio was €7208 for originator r-hFSH-alfa versus biosimilars. Drug acquisition costs for originator r-hFSH-alfa represented 10.5% of total costs in the base case analysis, and 6.2% in a treatment cycle resulting in live birth with one fresh embryo transfer. Results from the sensitivity analyses confirmed the robustness of the findings.